​

Karyopharm Therapeutics (KPTI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KPTI Stock Forecast

Karyopharm Therapeutics (KPTI) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $7.33, with a high of $14.00 and a low of $3.00. This represents a 994.03% increase from the last price of $0.67.

- $3 $6 $9 $12 $15 High: $14 Avg: $7.33 Low: $3 Last Closed Price: $0.67

KPTI Stock Rating

Karyopharm Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

KPTI Price Target Upside V Benchmarks

TypeNameUpside
StockKaryopharm Therapeutics994.03%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$0.67$0.67$0.67
Upside/Downside--347.76%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25421--7
Jan, 25421--7
Dec, 24421--7
Nov, 245511-12
Oct, 245511-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2024Brian AbrahamsRBC Capital$3.00$0.95215.79%347.76%
Jan 10, 2023Leerink Partners$5.00$2.8476.06%646.27%
Aug 23, 2022Collen KusyRobert W. Baird$14.00$5.56151.80%1989.55%
Mar 10, 2022Brian AbrahamsRBC Capital$8.00$6.4923.27%1094.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024Piper SandlerOverweightOverweighthold
Jul 01, 2024H.C. WainwrightBuyBuyhold
Jun 10, 2024RBC CapitalOutperformOutperformhold
Jan 10, 2023SVB LeerinkMarket PerformMarket Performhold
Nov 04, 2022RBC CapitalSector PerformOutperformupgrade
Mar 10, 2022RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.72$-1.65$-2.02$-1.25-----
Avg Forecast$-2.74$-2.62$-1.89$-1.20$-0.72$-0.74$-0.56$-0.02$-0.06
High Forecast$-3.14$-3.00$-2.16$-1.24$-0.83$-1.20$-0.71$-0.72$-0.07
Low Forecast$-2.35$-2.24$-1.65$-1.16$-0.62$-0.42$-0.31$0.74$-0.05
Surprise %-0.73%-37.02%6.88%4.17%-----

Revenue Forecast

$50M $110M $170M $230M $290M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$108.08M$209.82M$157.07M$146.03M-----
Avg Forecast$101.43M$133.12M$157.96M$147.69M$152.04M$165.50M$202.67M$293.88M$300.00M
High Forecast$90.14M$118.31M$142.55M$127.52M$148.71M$146.40M$174.99M$292.59M$259.02M
Low Forecast$112.75M$147.98M$174.96M$170.61M$155.37M$187.45M$234.12M$295.17M$346.55M
Surprise %6.56%57.62%-0.56%-1.12%-----

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-196.27M$-124.09M$-165.29M$-143.10M-----
Avg Forecast$-184.62M$-57.42M$-51.81M$-143.10M$-87.48M$-129.94M$-58.33M$-65.99M$-6.85M
High Forecast$-221.55M$-109.11M$-106.41M$-274.17M$-94.79M$-137.16M$-81.66M$-81.95M$-8.24M
Low Forecast$-147.70M$-5.72M$2.78M$-12.03M$-70.66M$-47.61M$-35.00M$83.95M$-5.64M
Surprise %6.31%116.12%219.01%------

KPTI Forecast FAQ

Is Karyopharm Therapeutics stock a buy?

Karyopharm Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Karyopharm Therapeutics is a favorable investment for most analysts.

What is Karyopharm Therapeutics's price target?

Karyopharm Therapeutics's price target, set by 4 Wall Street analysts, averages $7.33 over the next 12 months. The price target range spans from $3 at the low end to $14 at the high end, suggesting a potential 994.03% change from the previous closing price of $0.67.

How does Karyopharm Therapeutics stock forecast compare to its benchmarks?

Karyopharm Therapeutics's stock forecast shows a 994.03% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Karyopharm Therapeutics over the past three months?

  • February 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Karyopharm Therapeutics’s EPS forecast?

Karyopharm Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-0.72 for 2024, a -42.40% decrease from the reported $-1.25 in 2023. The prediction for 2025 is $-0.74, $-0.56 for 2026, $-0.02 for 2027, and $-0.06 for 2028.

What is Karyopharm Therapeutics’s revenue forecast?

Karyopharm Therapeutics's average annual revenue forecast for its fiscal year ending in December is $152.04M for 2024, a 4.11% increase from the reported $146.03M in 2023. The forecast for 2025 is $165.5M, $202.67M for 2026, $293.88M for 2027, and $300M for 2028.

What is Karyopharm Therapeutics’s net income forecast?

For its fiscal year ending in December, Karyopharm Therapeutics's average annual net income forecast is $-87.479M for 2024, reflecting a -38.87% decrease from the reported $-143M in 2023. The projection for 2025 is $-130M, $-58.329M for 2026, $-65.989M for 2027, and $-6.853M for 2028.